Tag: STEMI

Recardio’s Positive Phase 2 Results Presented as Latebreaker at World Congress on Acute Heart Failure 2022 in Madrid

Recardio Inc., a clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the positive study results of Recardio’s Phase 2 clinical study in Acute Myocardial Infarction were presented on Saturday, May 21, 2022, during the Latebreaker Session at the World Congress on Acute Heart Failure 2022 in […]

Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial Infarction

Iocyte AMI-3 Trial to Assess Effectiveness and Safety of FDY-5301 in Improving Outcomes for Anterior STEMI Patients Undergoing Primary PCI SEATTLE, May 10, 2022 (GLOBE NEWSWIRE) — Faraday Pharmaceuticals, Inc., today announced the enrollment of the first patient in its Iocyte AMI-3 study — a Phase 3 clinical trial assessing the efficacy […]

Recardio’s Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin Now Enrolling and Recruiting in All Global Centers

Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction is now enrolling and recruiting in all multiple European and U.S. centers. SAN FRANCISCO, Sept. 9, 2019 /PRNewswire/ — The clinical study is intended […]

PiCSO therapy reduces infarct size in STEMI patients.

AWANS, Belgium, May 24, 2018 /PRNewswire/ — Miracor Medical SA announced today the clinical results from the physician-sponsored OxAMI-PiCSO study were published in the EuroIntervention journal and presented at the Hotline session of the EuroPCR conference by Dr. Giovanni Luigi De Maria, MD, the Heart Centre, Oxford University Hospitals, Oxford, UK. The latest results, obtained with the PiCSO® Impulse System, contribute to the […]